Description
MODIFICATION TO IMPLEMENT EO 14398 DEI DISCRIMINATION.
Base award description: NEW AWARD FOR AMOXICILLIN/CLAVULANATE POTASSIUM (K) SUSPENSION WITH SANDOZ, INC. ORDERING PERIOD IS JANUARY 15, 2023, TO JANUARY 14, 2024, WITH FOUR ONE-YEAR OPTIONS.
Modification chain · 14 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2022-11-28+$0= $0
- Mod P000012023-01-11+$0= $0
- Mod P000022023-05-03+$0= $0
- Mod P000032023-12-18+$0= $0
- Mod P000042024-02-01+$0= $0
- Mod P000052024-02-15+$0= $0
- Mod P000062024-02-21+$0= $0
- Mod P000072024-11-05+$0= $0
- Mod P000082025-01-16+$0= $0
- Mod P000092025-08-05+$0= $0
- Mod P000102025-10-14+$0= $0
- Mod P000112025-12-15+$0= $0
- Mod P000122026-01-08+$0= $0
- Mod P000132026-09-03+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2022-11-28 | +$0 | $0 | NEW AWARD FOR AMOXICILLIN/CLAVULANATE POTASSIUM (K) SUSPENSION WITH SANDOZ, INC. ORDERING PERIOD IS JANUARY 15… |
| Mod P00001· ADD SUBCONTRACTING PLAN | 2023-01-11 | +$0 | $0 | INCORPORATE THE 2023 APPROVED SMALL BUSINESS SUBCONTRACTING PLAN. |
| Mod P00002· OTHER ADMINISTRATIVE ACTION | 2023-05-03 | +$0 | $0 | ADMINISTRATIVE MODIFICATION TO ADD DRUG SUPPLY CHAIN SECURITY ACT LANGUAGE TO CONTRACT. |
| Mod P00003· EXERCISE AN OPTION | 2023-12-18 | +$0 | $0 | MODIFICATION TO EXERCISE OPTION YEAR 1. PERIOD OF PERFORMANCE IS 1/15/2024 TO 1/14/2025. |
| Mod P00004· ADD SUBCONTRACTING PLAN | 2024-02-01 | +$0 | $0 | MODIFICATION TO ADD 2024 SUBCONTRACTING PLAN. EFF. 1/1/2024 - 12/31/2024 |
| Mod P00005· OTHER ADMINISTRATIVE ACTION | 2024-02-15 | +$0 | $0 | MODIFICATION TO CHANGE POC FROM EVELYN BERGMAN TO ERIC SHINN |
| Mod P00006· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2024-02-21 | +$0 | $0 | UPDATE CRF PAYMENT SUBMITTAL AND SALES REPORTING |
| Mod P00007· EXERCISE AN OPTION | 2024-11-05 | +$0 | $0 | EXERCISE OPTION YEAR 2 FOR AMOXICILLIN/CLAVULANATE K SUSPENSION WITH SANDOZ, INC. PERFORMANCE PERIOD IS 1/15/2… |
| Mod P00008· ADD SUBCONTRACTING PLAN | 2025-01-16 | +$0 | $0 | INCORPORATE CONTRACTOR'S 2025 SMALL BUSINESS SUBCONTRACTING PLAN INTO CONTRACT. |
| Mod P00009· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2025-08-05 | +$0 | $0 | ADD NEW NDC FOR TWO LINE ITEMS. |
| Mod P00010· OTHER ADMINISTRATIVE ACTION | 2025-10-14 | +$0 | $0 | DELETE NDC FOR TWO LINE ITEMS. |
| Mod P00011· EXERCISE AN OPTION | 2025-12-15 | +$0 | $0 | EXERCISE OPTION YEAR 3 WITH NO PRICE CHANGES. |
| Mod P00012· ADD SUBCONTRACTING PLAN | 2026-01-08 | +$0 | $0 | INCORPORATE SANDOZ 2026 SUBCONTRACTING PLAN. |
| Mod P00013· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2026-09-03 | +$0 | $0 | MODIFICATION TO IMPLEMENT EO 14398 DEI DISCRIMINATION. |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI ETJGHMFH1MT5)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36F79723D0187 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36E79723D0001 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36E79722D0033 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
| 36E79722D0016 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
| 36E79722D0011 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
| 36E79721D0010 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2021 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79723D0005_3600 · retrieved 2026-09-26.